Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 7/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KIF5B | P33176 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052304 | 0.88 | FGFR1 (0.54) | FGFR1FLT1EGFRGAKKDR | |
| SCHEMBL14756275 | 0.84 | EGFR (0.45) | EGFRGAKKDRRETKIF5B | |
| SCHEMBL16618967 | 0.80 | ENPP1 (0.34) | FGFR1FLT1 | |
| SCHEMBL24677720 | 0.80 | L3MBTL1 (0.36) | FGFR1FLT1EGFRKDRKDM1A | |
| SCHEMBL12496270 | 0.78 | EGFR (0.45) | EGFRGAKKDRRETKIF5B | |
| SCHEMBL15578423 | 0.78 | FLT1 (0.45) | FGFR1FLT1EGFRGAKKDR | |
| SCHEMBL16619722 | 0.78 | SLC22A12 (0.35) | EGFR | |
| SCHEMBL30878050 | 0.74 | CGAS (0.35) | EGFRGAK | |
| SCHEMBL21404361 | 0.74 | CGAS (0.35) | EGFRGAK | |
| SCHEMBL165285 | 0.74 | PDGFRB (0.55) | EGFRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |